CSF SERPINA3 Levels Are Elevated in Patients With Progressive MS

Research output: Contribution to journalJournal articlepeer-review

Documents

  • Fulltext

    Final published version, 1.36 MB, PDF document

  • Nicolás Fissolo
  • Clara Matute-Blanch
  • Osman, Mudi
  • Carme Costa
  • Rucsanda Pinteac
  • Berta Miró
  • Alex Sanchez
  • Verónica Brito
  • Irena Dujmovic
  • Margarete Voortman
  • Michael Khalil
  • Eva Borràs
  • Eduard Sabidó
  • Issazadeh-Navikas, Shohreh
  • Xavier Montalban
  • Manuel Comabella Lopez

OBJECTIVE: To identify biomarkers associated with progressive phases of MS and with neuroprotective potential.

METHODS: Combined analysis of the transcriptional and proteomic profiles obtained in CNS tissue during chronic progressive phases of experimental autoimmune encephalomyelitis (EAE) with the transcriptional profile obtained during the differentiation of murine neural stem cells into neurons. Candidate biomarkers were measured by ELISA in the CSF of 65 patients with MS (29 with relapsing-remitting MS [RRMS], 20 with secondary progressive MS, and 16 with primary progressive MS [PPMS]) and 30 noninflammatory neurologic controls (NINCs).

RESULTS: Integrative analysis of gene and protein expression data identified 2 biomarkers, the serine protease inhibitor Serpina3n and the calcium-binding protein S100A4, which were upregulated in chronic progressive EAE and whose expression was induced during neuronal differentiation. Immunofluorescence studies revealed a primarily neuronal expression of S100A4 and Serpina3n during EAE. CSF levels of SERPINA3, the human ortholog of murine Serpina3n, and S100A4 were increased in patients with MS compared with NINCs (SERPINA3: 1,320 vs 838.6 ng/mL, p = 0.0001; S100A4: 1.6 vs 0.8 ng/mL, p = 0.02). Within the MS group, CSF SERPINA3 levels were significantly elevated in patients with progressive forms, mainly patients with PPMS compared with patients with RRMS (1,617 vs 1,129 ng/mL, p = 0.02) and NINCs (1,617 vs 838.6 ng/mL, p = 0.0001). Of interest, CSF SERPINA3 levels significantly correlated with CSF neurofilament light chain levels only in the PPMS group (r = 0.62, p = 0.01).

CONCLUSION: These results point to a role of SERPINA3 as a biomarker associated with the progressive forms of MS, particularly PPMS.

Original languageEnglish
JournalNeurology: Neuroimmunology & Neuroinflammation
Volume8
Issue number2
Number of pages17
ISSN2332-7812
DOIs
Publication statusPublished - 2021

Bibliographical note

Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

Number of downloads are based on statistics from Google Scholar and www.ku.dk


No data available

ID: 255357432